DCGI approved Itolizumab to treat COVID-19 patients with moderate to severe acute respiratory distress
India’s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for “restricted emergency use” to treat COVID-19 patients... Read More
Aurobindo Pharma hives off its biosimilars business to subsidiary CuraTeQ Biologics
Aurobindo Pharma hives off its biosimilars business to wholy-owned subsidiary ‘CuraTeQ Biologics Private Limited’ for a cash consideration of ₹361.46 crore. The... Read More
AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins... Read More
Market Exclusivity Case Study: XIFAXAN (rifaximin)
Posted on07 May 2020
Comments0
Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, which is one of the largest specialty pharmaceutical companies in... Read More
Bausch + Lomb – Stada Arzneimittel – Xbrane Biopharma – licensing deal for Lucentis biosimilar
Bausch + Lomb announced an exclusive licensing agreement with Stada Arzneimittel and its development partner Xbrane Biopharma to develop and commercialize a... Read More
Valneva And Pfizer to Co-Develop and Commercialize Lyme Disease Vaccine, Vla15
Valneva SE, a specialty vaccine company, and Pfizer Inc. today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate... Read More
Ipsen agreement with IRICoR & Université de Montréal to acquire exclusive license for discovery-stage oncology programme
Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, announced they... Read More
Global Licensing Agreement Case study: ProThera Biologics and Takeda to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)
Posted on24 Apr 2020
Comments0
ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor... Read More
Gilead Sciences, Second Genome ink collaboration strategic deal in biomarker and inflammatory bowel disease drug discovery
Gilead Sciences, Inc and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration... Read More
Who determines when a prescription medicine should be switched to OTC status?
Posted on07 Apr 2020
Comments0
Technically, anyone could submit a Citizen’s Petition to FDA to switch a product from Rx to OTC status. However, the holder of... Read More